Clinical trials: Mycobacterium Avium Intracellulare Complex (MAC)
- Condition Mycobacterium Avium Intracellulare Complex (MAC)
- Funder type Industry (pharma, biotech, devices)
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.
To determine the antimicrobial activity and tolerability of rifapentine alone and in combination therapy in patients with AIDS and disseminated Mycobacterium avium complex (MAC) bacteremia.
- Trial name
- NCT00002192
- Testing
- Rifapentine, Ethambutol hydrochloride, Clarithromycin
- Where
- United States
- Sponsor
- Anderson Clinical Research
Mycobacterium Infections, Nontuberculous
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
The main objective of this study is to evaluate the efficacy of ALIS (amikacin liposome inhalation suspension) + background regimen (azithromycin [AZI] + ethambutol [ETH]) compared to the ELC (empty liposome control) + background…
- Trial name
- ENCORE (NCT04677569)
- Testing
- ALIS, Azithromycin, Ethambutol
- Where
- 258 sites in United States, Argentina and 21 more
- Volunteers
- 425 people
- Sponsor
- Insmed Incorporated
Mycobacterium Avium-intracellulare Infection, HIV Infections
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
The primary objectives of this trial are: To compare the safety of oral rifabutin versus placebo in the treatment of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200…
- Trial name
- NCT00002032
- Testing
- Rifabutin
- Where
- 33 sites in United States
- Volunteers
- 750 people
- Sponsor
- Pharmacia
NTM Lung Infection Due to MAC
Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212
This is an open-label safety extension study to assess the safety and tolerability of once daily dosing of 590 mg Liposomal Amikacin for Inhalation (LAI) added to a multi-drug regimen in participants with nontuberculous…
- Trial name
- NCT02628600
- Testing
- LAI 590 mg, Multi-drug regimen
- Volunteers
- 163 people
- Sponsor
- Insmed Incorporated
Mycobacterium Avium-Intracellulare Infection, HIV Infections
A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients
To evaluate the efficacy and safety of azithromycin administered once a week in the prevention of disseminated Mycobacterium avium complex (MAC) in severely immunocompromised HIV-infected patients with a CD4 count < 100 cells/mm3.
- Trial name
- NCT00002309
- Testing
- Azithromycin
- Where
- 3 sites in United States
- Sponsor
- Pfizer
Mycobacterium Avium-Intracellulare Infection, HIV Infections
A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS
To determine if a drug regimen containing rifabutin will eradicate or decrease the numbers of Mycobacterium avium complex (MAC) organisms in blood, improve the symptoms associated with MAC infection, and increase survival in…
- Trial name
- NCT00001995
- Testing
- Rifabutin
- Where
- 22 sites in United States
- Volunteers
- 200 people
- Sponsor
- Pharmacia
Mycobacterium Avium-Intracellulare Infection, HIV Infections
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.
- Trial name
- NCT00002170
- Testing
- Nelfinavir mesylate
- Where
- 5 sites in United States
- Sponsor
- Agouron Pharmaceuticals
Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis
A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients
The purpose of this open-label, multicenter, non-randomized, pilot study is to assess the safety of high dose intermittent iNO for treatment of NTM infection in CF and non-CF patients.
- Conditions
- Non-Tuberculous Mycobacterial Pneumonia, Cystic Fibrosis, Mycobacterial Pneumonia, Mycobacterium Abscessus Infection
- Trial name
- NCT04685720
- Testing
- LungFit
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Beyond Air Inc.